Skip to main content
TipRanks
Go Ultimate75% OFF

FDC Ltd. (FDC) AI Stock Analysis

0 Followers
IN:FDC

FDC Ltd.

(NSE:FDC)

Select Model
Rating:60Neutral
Price Target:INR 398.00â–²(5.61% Upside)
Action:reiterated
Date:08/28/26

FDC earns a moderate score. Its greatest strength is a virtually debt-free balance sheet with consistently growing equity and assets, supported by steady mid-single-digit revenue growth. However, profitability has eroded meaningfully — net margins have nearly halved since FY2021 — and free cash flow is projected to fall sharply in FY2026, raising questions about capital allocation. Technicals are the main near-term drag, with the stock below all key moving averages and negative MACD momentum, although oversold RSI and Stochastic readings suggest downside may be stretched. Valuation at ~19x earnings with a 1.4% yield is fair rather than compelling, leaving the shares fundamentally sound but lacking near-term catalysts.

Positive Factors
Steady revenue growthSteady revenue expansion indicates resilient demand for FDC’s pharmaceutical and healthcare products across its served channels. Continued top-line growth can support operating scale, product investment, and customer reach, providing a durable foundation for earnings over the next several quarters.
Negative Factors
Margin deteriorationFalling and inconsistent margins indicate that FDC is not converting revenue into profit as efficiently as it did at earlier peaks. Potential cost, product-mix, or pricing pressure could limit earnings growth and make future profitability less predictable even while revenue continues to expand.

FDC Ltd. (FDC) vs. iShares MSCI India ETF (INDA)

-25%-20%-15%-10%-5%0%5%10%IN:FDC-7.96%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 60.35B
Dividend Yield
1.32%
Average Volume (3M)
11.58K
Price to Earnings (P/E)
19.5
Beta (1Y)
0.75
Revenue Growth
10.20%
EPS Growth
38.95%
Country
India
Employees
7,076
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

FDC Ltd. Business Overview & Revenue Model

Company Description

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectiv...

How the Company Makes Money

FDC makes money primarily by selling pharmaceutical and healthcare products. Revenue is generated from (1) sales of prescription medicines supplied to healthcare providers, hospitals, and pharmacies, and (2) sales of other healthcare products sold th...

FDC Ltd. Financial Statement Overview

Summary

A fortress balance sheet (score 85) anchors the profile — debt of just ₹212M against ₹22.8B equity (D/E under 1%), steadily rising assets and equity. The income statement (62) shows consistent revenue growth from ₹13.3B (FY2021) to ₹21.1B (FY2025) with ₹21.7B projected for FY2026, but net margins have roughly halved from ~23% to ~13% and EBITDA margins compressed from ~32% to ~20%. Cash flow (58) is the weakest link: FY2025 operating cash flow was strong at ₹3.64B with ~1.0x conversion of net income, yet free cash flow is projected to fall sharply to ₹623M in FY2026, pointing to heavy capex or working capital absorption.

Income Statement

62Positive

Balance Sheet

85Very Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue22.89B21.71B21.08B19.35B17.84B15.26B
Gross Profit9.74B9.18B8.36B6.51B11.28B9.78B
EBITDA3.79B4.39B4.15B4.40B3.01B3.30B
Net Income3.13B2.81B2.67B3.05B1.94B2.16B
Balance Sheet
Total Assets31.76B29.19B27.14B24.68B23.43B22.70B
Cash, Cash Equivalents and Short-Term Investments6.22B5.23B5.37B4.75B4.84B5.39B
Total Debt128.20M154.65M211.68M205.19M283.20M322.04M
Total Liabilities5.07B4.34B4.33B3.71B3.62B3.14B
Stockholders Equity26.69B24.85B22.81B20.97B19.82B19.57B
Cash Flow
Free Cash Flow0622.92M2.67B1.27B418.21M291.08M
Operating Cash Flow02.49B3.64B2.21B1.55B1.62B
Investing Cash Flow0-1.59B-2.47B-170.83M111.35M-1.45B
Financing Cash Flow0-925.39M-913.47M-2.02B-1.80B-98.37M

FDC Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price376.85

Price Trends

50DMA355.35Positive
100DMA373.02Positive
200DMA370.67Positive

Market Momentum

MACD9.06Positive
RSI54.77Neutral
STOCH24.99Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FDC, the sentiment is Positive. The current price of 376.85 is above the 20-day moving average (MA) of 372.03, above the 50-day MA of 355.35, and above the 200-day MA of 370.67, indicating a bullish trend. The MACD of 9.06 indicates Positive momentum. The RSI at 54.77 is Neutral, neither overbought nor oversold. The STOCH value of 24.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:FDC.

FDC Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:FDC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:STARIN:STAR77OutperformINR 90.65B14.68―0.51%11.28%55.18%
IN:BLISSGVSIN:BLISSGVS65NeutralINR 70.10B43.41―0.23%24.87%46.37%
IN:FDCIN:FDC60NeutralINR 61.35B19.54―1.32%10.20%38.95%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ORCHPHARMAIN:ORCHPHARMA54NeutralINR 55.82B544.36――10.83%-89.83%
IN:UNICHEMLABIN:UNICHEMLAB51NeutralINR 33.90B10.00――6.44%283.10%
IN:INDOCOIN:INDOCO50NeutralINR 20.73B66.15―0.09%10.75%―

* General Sector Average

Performance Comparison

0%100%200%300%IN:FDCIN:BLISSGVSIN:INDOCOIN:ORCHPHARMAIN:STARIN:UNICHEMLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:FDC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:FDCFDC Ltd.376.85-28.54-7.04%
IN:BLISSGVSBliss Gvs Pharma Limited659.25499.06311.55%
IN:INDOCOIndoco Remedies Limited224.60-37.87-14.43%
IN:ORCHPHARMAOrchid Pharma Limited932.2082.359.69%
IN:STARStrides Pharma Science Ltd983.4526.732.79%
IN:UNICHEMLABUnichem Laboratories Limited481.450.000.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 28, 2026